Kenvue Inc. (NYSE:KVUE) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its stake in Kenvue Inc. (NYSE:KVUEFree Report) by 4.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 133,737 shares of the company’s stock after acquiring an additional 5,353 shares during the quarter. Rafferty Asset Management LLC’s holdings in Kenvue were worth $2,879,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Beaumont Financial Advisors LLC lifted its holdings in shares of Kenvue by 3.0% in the 4th quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock worth $377,000 after acquiring an additional 509 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in shares of Kenvue by 51.3% in the 4th quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock worth $33,000 after acquiring an additional 526 shares during the last quarter. Tradition Wealth Management LLC lifted its holdings in shares of Kenvue by 2.8% in the 4th quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after acquiring an additional 575 shares during the last quarter. Dfpg Investments LLC lifted its holdings in shares of Kenvue by 2.3% in the 4th quarter. Dfpg Investments LLC now owns 26,659 shares of the company’s stock worth $567,000 after acquiring an additional 589 shares during the last quarter. Finally, Mutual Advisors LLC lifted its holdings in shares of Kenvue by 6.1% in the 4th quarter. Mutual Advisors LLC now owns 10,606 shares of the company’s stock worth $228,000 after acquiring an additional 612 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 1.3 %

Shares of NYSE:KVUE opened at $18.39 on Friday. Kenvue Inc. has a 52 week low of $17.82 and a 52 week high of $26.74. The company’s 50 day moving average is $19.63 and its two-hundred day moving average is $20.17. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company has a market cap of $35.21 billion and a PE ratio of 23.58.

Kenvue (NYSE:KVUEGet Free Report) last posted its earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The firm had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm’s revenue for the quarter was down 24.9% compared to the same quarter last year. Equities analysts predict that Kenvue Inc. will post 1.18 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.35%. The ex-dividend date of this dividend was Tuesday, May 7th. Kenvue’s dividend payout ratio (DPR) is 102.56%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on KVUE. Sanford C. Bernstein began coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. Citigroup reaffirmed a “neutral” rating and set a $21.00 target price on shares of Kenvue in a research note on Tuesday, May 28th. William Blair began coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. Finally, HSBC upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $23.09.

View Our Latest Analysis on KVUE

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Featured Stories

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.